In a response for yesterday’s press releases on a new potential revolutionary drug for diabetes that had negative trading impact on Bioton, the CEO Adama Wilczega commented in the daily Parkiet that this is going to influence Bioton’s strategy, which takes into account the risk of such inventions. The time lag between laboratory works and launching of new drug on the market it at least 10 years. Addionally, according to press releases the new drug treats only type one diabetes, which affects only 10-15% of patients.
Our view: The CEO comments could have a positive trading impact.